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Background: Vascular endothelial growth factor receptor 2 (VEGFR2) is a crucial mediator of tumour angiogenesis.
High expression levels of the receptor have been correlated to poor prognosis in cancer patients. Reliable imaging
biomarkers for stratifying patients for anti-angiogenic therapy could therefore be valuable for increasing treatment
success rates. The aim of this study was to investigate the pharmacokinetics and angiogenesis imaging abilities of
the VEGFR2-targeting positron emission tomography (PET) tracer (R)-[11C]PAQ.
Methods: (R)-[11C]PAQ was evaluated in the mouse mammary tumour virus-polyoma middle T (MMTV-PyMT) model
of metastatic breast cancer. Mice at different stages of disease progression were imaged with (R)-[11C]PAQ PET, and
results were compared to those obtained with [18 F]FDG PET and magnetic resonance imaging. (R)-[11C]PAQ uptake
levels were also compared to ex vivo immunofluorescence analysis of tumour- and angiogenesis-specific biomarkers.
Additional pharmacokinetic studies were performed in rat and mouse.
Results: A heterogeneous uptake of (R)-[11C]PAQ was observed in the tumorous mammary glands. Ex vivo analysis
confirmed the co-localization of areas with high radioactivity uptake and areas with elevated levels of VEGFR2. In some
animals, a high focal uptake was observed in the lungs. The lung uptake correlated to metastatic and angiogenic
activity, but not to uptake of [18 F]FDG PET. The pharmacokinetic studies revealed a limited metabolism and excretion
during the 1-h scan and a distribution of radioactivity mainly to the liver, kidneys and lungs. In rat, a high uptake was
additionally observed in adrenal and parathyroid glands.
Conclusion: The results indicate that (R)-[11C]PAQ is a promising imaging biomarker for visualization of angiogenesis,
based on VEGFR2 expression, in primary tumours and during metastasis development.
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Vascular endothelial growth factor receptor 2 (VEGFR2)
is a receptor tyrosine kinase that is a key mediator
of vascular endothelial growth factor (VEGF)-stimulated
proangiogenic signalling and is often overexpressed on
activated endothelial cells in the tumours [1,2]. Several
studies have implicated a close relationship between high
VEGFR2 expression in tumours and invasive and meta-
static behaviour, increased proliferation and poor patient* Correspondence: erik.samen@ki.se
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in any medium, provided the original work is pprognosis [3-6]. For example, the tumour VEGFR2 expres-
sion in patients with invasive premenopausal breast cancer
was found to be a prognostic marker for the response to
oestrogen receptor-targeted therapy [7]. Anti-angiogenic
therapy inhibits receptor signalling and has improved
patient outcome in several types of cancer, e.g. glioblast-
oma and renal cell cancer. However, despite initially
encouraging results, breast cancer studies have reported
that anti-angiogenic treatment increases progression free
survival but not overall survival compared to standard
cytostatic treatment [8]. Finding reliable and accurate
methods to individualize therapy is a high priority for can-
cer treatment of the future [9] and critical for increasingn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Samén et al. EJNMMI Research 2014, 4:17 Page 2 of 11
http://www.ejnmmires.com/content/4/1/17the overall benefit of anti-angiogenic therapy. Determining
the extent to which these methods can identify and quan-
tify molecular dysfunctions and therapeutic responses in
preclinical models is a key step toward accelerating future
translation to human studies.
We have previously reported promising positron
emission tomography (PET) molecular imaging with the
carbon-11-labelled VEGFR2-targeting tracer (R,S)-N-
(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-11C-methyl-
3-piperidinyl)methoxy)-4-quinazolinamine ([11C]PAQ) [10].
Structurally, PAQ closely resembles the anti-angiogenic
drug ZD6474 (Vandetanib) with exception for the chirality
of the molecule and the reported 40 times stronger inhibi-
tory properties (IC50 = 1 nM, R-isomer) for the VEGFR2,
making it an attractive candidate as an imaging tracer
[11]. The tracer demonstrated excellent in vivo stability
and favourable pharmacokinetic behaviour. The uptake of
radioactivity in vivo correlated well with ex vivo phosphor
imaging and immunofluorescence (IF) performed post-
mortem, demonstrating high levels of radioactivity and
VEGFR2, respectively, in the same tumour areas. The
subcutaneous xenograft cancer provided important indi-
cations that [11C]PAQ could potentially be a valuable
tracer with the ability to visualize regions with high
VEGFR2 expression. Here, we have now developed a syn-
thesis for the R-stereoisomer of the labelled tracer, based
on the reported 10-fold lower IC50 value for the VEGFR2
and a 200-fold better selectivity versus the epidermal
growth factor receptor for the R- compared to the S-
isomer [11].
The ability of the carbon-11-labelled analogue of (R)-
N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-3-
piperidinyl)methoxy)-4-quinazolinamine ((R)-[11C]PAQ) to
detect levels of VEGFR2 in vivo is evaluated here in a
transgenic mouse model of metastatic breast cancer, in
which the expression of the polyoma middle T antigen
(PyMT) oncoprotein is controlled by the mouse mammary
tumour virus (MMTV). In the FVB genetic background,
invasive mammary tumours and subsequent pulmonary
metastases develop over 12 to 15 weeks. The model
demonstrates gradual progression and significant stromal
infiltration. It has been well characterized and shown to
have a good translational potential [12]. Outgrowth of
micrometastases in the MMTV-PyMT model has been
shown to be dependent on endothelial progenitor cell
infiltration followed by a distinct growth acceleration
which correlated with an increased vascularization [13].
These features make this model attractive for evaluating
novel PET radiotracers in a preclinical imaging setting. In
this study, the MMTV-PyMT animals were injected with
(R)-[11C]PAQ and scanned with PET at the age of 11 to
15 weeks when the presence of primary tumours had been
confirmed by palpation and metastatic events in lung
tissue could be expected.Our goal was to evaluate the capability of (R)-[11C]
PAQ to stratify levels of VEGFR2 during cancer deve-
lopment in the MMTV-PyMT model. The PET imaging
results were compared to ex vivo phosphor imaging (PI)
of malignant tissue combined with immunofluorescence
(IF) analyses of several molecular components involved
in angiogenesis and metastatic spread, including the
VEGFR2. We also compare the uptake patterns of (R)-
[11C]PAQ with 2-[18 F]-fluoro-2-deoxy-D-glucose ([18 F]
FDG) PET in tumour and lung tissue. In addition to the




A more detailed description of the synthesis of the precur-
sor and radiolabelling can be found in Additional file 1.
(R)-[11C]PAQ was produced according to Figure 1. The
N-desmethyl (R)-precursor #1 was synthesized with an
enantiomeric purity of >99%. Radiolabeling was accom-
plished using [11C]methyliodide prepared by methods first
described in [14]. (R)-[11C]PAQ, #2, so prepared had a
radiochemical purity of >98% and a specific activity ty-
pically of 1,000 to 2,000 GBq/μmol at injection. Decay-
corrected radiochemical yield was approximately 10% at
the end of synthesis. [2-18 F]-2-Fluoro-2-deoxy-D-glucose
([18 F]FDG), was obtained from batches made for clinical
PET and had passed standard quality controls for Fludeox-
yglucose (18 F) Karolinska.
Animals and treatment
All experiments involving animals were conducted
according to the research plan and regulations of the
Karolinska Institutet and were approved by the local
laboratory animal ethics committee (N325/09 with ad-
dendums N85/11 and N65/12). At the time of the
study, the MMTV-PYMT mice (n = 11, 19 to 28 g, 11
to 15 weeks) had palpable tumours in at least one of
the mammary glands. The female wild-type (WT) controls
(n = 3, 18 to 23 g, 13 to 15 weeks) were healthy siblings to
the MMTV-PyMT mice. The male Sprague-Dawley rats
(Scanbur, Sollentuna, Sweden) (n = 3) used for metabolite
assays and biodistribution experiments weighed 420 to
421 g and were 15 to 17 weeks old. Animals were housed
under standard conditions according to local regulations
with food and water ad lib.
Metabolite assay
The rat was anaesthetized and placed on a heating pad
(37°C) on the operating table. A PE-50 catheter was
inserted into the femoral artery, and blood samples
(300 μl) were collected via the catheter at 30 and 60 min
after i.v. injection of 62.5 MBq of (R)-[11C]PAQ. The
Figure 1 Synthesis of precursor and radiolabeling. (A) Triethylamine, dichloromethane, 23°C, 2 h. (B) K2CO3, dimethylformamide, 95°C, 2 h. (C)
Trifluoroacetic acid, dichloromethane, 23°C, 3 h. (D) [11C]CH3I, K2CO3, dimethylformamide, 95°C, 5 min.
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was collected from the bladder.
Blood and urine samples were added to plastic tubes
containing heparin (50 μl, 5 IU/ml) and centrifuged
(950 g, 2 min). The supernatant was transferred to a new
tube and acetonitrile (200 μl) was added; the tube was
then vortexed for a few seconds to mix and allow precipi-
tation of proteins before centrifugation (950 g, 2 min). The
resulting protein-free supernatant was injected on the
HPLC system, and 20-s fractions were collected and mea-
sured in a gamma counter (1480 Wizard 3", PerkinElmer,
Waltham, MA, USA).
The liquid chromatography (LC) system used for
analysis of blood and urine samples consisted of a LC
pump (Shimadzu LC-10 AD, Shimadzu, Kyoto, Japan), a μ-
Bondapak C18 column (300 × 7.8 mm, 10 μm (Waters
Corporation, Milford, MA, USA); mobile phase CH3CN:
0.05 M NH4OAc 70:30 v/v; 7 ml/min) and a UV detector(Shimadzu) (λ = 254 nm) in series with a Beckman model
170 radiodetector (Beckman Coulter, Brea, CA, USA).
Shimadzu Class VP software was used for the processing
of the LC data.
PET and MRI imaging
In vivo PET investigations were performed using a micro-
PET Focus 120 scanner (CTI Concorde Microsystems,
Knoxville, TN, USA). In the biodistribution assay, the rat
was scanned using a continuous bed motion protocol to
generate a whole-body image dataset. The MMTV-PyMT
mice and controls were placed with the whole body in the
field of view (7.68 cm). List mode data, collected continu-
ously over 60 min (40 min for 18 F-FDG) starting at time
of injection, were reconstructed by standard 2-D filtered
back projection using a ramp filter. The matrix size of the
reconstructed images was 256 × 256 × 95 with a spatial
resolution of 1.3 mm. Data were normalized and corrected
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were processed using MicroPET Manager and evaluated
using the Inveon Research Workplace (IRW) software
(Siemens Medical Systems, Malvern, PA, USA). (R)-[11C]
PAQ and [18 F]FDG were administered via the tail vein
(maximum 200 μl in mice and 1,000 μl in rat). Doses of
(R)-[11C]PAQ injected ranged from 0.10 to 0.38 MBq/g in
mice, and the rats used in the biodistribution assays
received doses of 0.15 and 0.024 MBq/g of (R)-[11C]PAQ
and (R,S)-[11C]PAQ, respectively.
Regions of interest (ROIs) delineating organs and
tissues were drawn on the images of the healthy animals
used in the biodistribution studies (Figure 2). To esti-
mate the blood levels of radioactivity, a ROI was drawn
over the inferior vena cava 0 to 30 s post-injection.
Assuming a tissue density of 1 g/ml, the radioactivity
concentrations were divided by the administered activity
to obtain ROI-derived percent injected dose per gram of
tissue (%ID/g). Radioactivity concentrations (Bq/mL)
were calculated automatically by calibrating against a
phantom with a known concentration.
In the MMTV-PyMT mice, uptake of (R)-[11C]PAQ in
the mammary gland tumour tissue was estimated by
drawing a ROI over the upper right mammary gland.
This position was chosen since the uptake here is least
affected by spillover effects from other organs and tis-
sues in these small animals. The mammary glands in the
control animals were not visible in the PET images, and
the ROIs were here placed in the area where the glands
are normally located, an area with homogenously low nor-
mal uptake of [11C]PAQ. Lung uptake was assessed using
a ROI created in the lungs at time frames that allowed
good delineation from the heart and liver. Mean and max-
imum standardized uptake values (SUVmean and SUVmax)
during the 20- to 60-min time period, when uptake had
plateaued, were automatically calculated from the ROI.
Four animals (two MMTV-PyMT and two WT control
animals) were injected with [18 F]FDG (0.3 to 0.4 MBq/g)
100 min after administration of (R)-[11C]PAQ and
scanned for 40 min starting at time of injection. These an-
imals were subsequently euthanized in the PET camera by
an increased isoflurane concentration and moved to a
9.4 T MR scanner (Varian, Yarnton, UK) with efforts taken
to minimize changes in body position. The animal holder
with the mouse body was mounted in the scanner equip-
ped with a volume coil of 40 mm inner diameter. The bod-
ies were scanned using the spoiled 3-D gradient echo
sequence (tr/te = 30/2.4 ms, flip angle = 11°). The matrix
size was 512 × 192 × 192 covering a field of view of 80 ×
30 × 30 mm3. The data were zero-filled to 512 × 256 × 256
before Fourier transformation to yield a voxel size of 156 ×
117 × 117 μm3.
MRI data were acquired and reconstructed using the
VnmrJ3.2 (Agilent Technologies, Santa Clara, CA, USA)software. Images were subsequently converted to Siemens/
Concorde format via ImageJ (NIH, Bethesda, MD, USA)
and AMIDE, imported to IRW and fused with the PET
images for further analysis.
Phosphor imaging
Lung and tumour tissue were excised from five MMTV-
PyMT mice and cut into sections (25 μm) for PI and IF.
Three mice were euthanized directly after the 60-min
(R)-[11C]PAQ PET scan and two 30 min after tracer
injection without undergoing PET. Lung tissue was
fixated with OCT/PBS (1:1) (n = 4) through a needle in
the trachea, and at least one of the mammary glands was
removed. Tissues were snap frozen in isopentane, chilled
with dry ice. Sections were cut from mammary glands
with visible tumours and from the lung tissue of the
MMTV-PyMT animals using a cryomicrotome (CM
3050S, Leica Microsystems, Wetzlar, Germany) and were
placed on Superfrost Plus microscope slides (Menzel-
Glaser, Braunschweig, Germany). The tissue sections
were exposed for 60 min and subsequently read using a
Typhoon 7000 FLA (GE Healthcare, Little Chalfront,
UK) with the ImageQuantTL software (GE Healthcare).
The digital images were analysed and processed using
the ImageJ software (NIH, USA).
Immunofluorescence
The same sections used for PI and additional sections
from mammary gland and lung tissue from several
animals were subjected to IF analysis. Sequential multi-
plex staining procedures were performed according to
standard protocols using a combination of fluorescence-
conjugated secondary antibodies and the tyramide signal
amplification (TSA) method [15]. Briefly, sections were
immersed in fixative (4% paraformaldehyde in 0.1 M
phosphate buffer, pH 7.4). After washing in PBS, endo-
genous peroxidase activity was blocked by incubation in
PBS containing 0.003% H2O2. Sections were incubated
overnight with a rat anti-polyoma virus antibody (PyMT,
4°C, 1:5,000, clone NS1, ABCAM ab15085, Abcam,
Cambridge, UK). Immunoreactivity was visualized using
HRP-conjugated donkey anti-rat IgG (1:200, Jackson
Immunoresearch, West Grove, PA, USA) and fluores-
cein-conjugated TSA (1:100, PerkinElmer). Sequential
sections were incubated overnight in rat anti-CD31 (4°C,
1:100, clone; MEC13.3, BD Pharmingen, San Diego, CA,
USA) followed by Alexa 594-conjugated donkey anti-rat
IgG (1:200, Jackson Immunoresearch). Finally, sections
were incubated overnight in rabbit anti-VEGFR2 (4°C,
1:2,000, Cell Signaling 55B11, Cell Signaling Technology,
Danvers, MA, USA) and developed using HRP-conju-
gated swine anti-rabbit IgG (Dako, Glostrup, Denmark)
and Cy5-conjugated TSA (1:100, PerkinElmer). Nuclei
were stained using Hoechst 33342 (1:10,000).
Figure 2 Time activity curves and PET images. Time activity curves and PET images (3-D volume rendering technique) over 60 min for a (A, B)
WT mouse and (D, E) WT rat after injection of (R)-[11C]PAQ and a comparison of biodistributions for (R)-[11C]PAQ and (R,S)-[11C]PAQ in (C) mice
and (F) rats. Organs and tissues examined are the same in both species except the adrenals, which could not be satisfactorily delineated in the
mouse. (C) and (F) display the uptake in the liver, kidney and lung at early (9 to 11 min) and late (55 to 60 min) time points after injection of
(R)-[11C]PAQ or (R,S)-[11C]PAQ in rat and mouse, respectively.
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ROMAT 10×/0.45) primary objective on a Vslide slide-
scanning microscope (Metasystems, Altlußheim, Germany)
equipped with filter sets for DAPI (EX350/50 - EM470/40),
FITC (EX493/16 - EM527/30), Cy3.5 (EX581/10 - EM617/40) and Cy5 (EX630/20 - 647/long pass). Individual
field-of-view images were stitched to produce images
of entire lung sections with microscopic resolution.
Images were analysed using the MetaViewer software
(Metasystems).
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Biodistribution and metabolism of (R)-[11C]PAQ in
wild-type rodents
High radioactivity uptakes were observed in the liver,
kidney and lung with highest retention in the liver
(Figure 2A,D). In the rat, noticeable uptakes were also
found in the thymus and parathyroid glands, and highest
overall uptake was in the adrenal glands. The whole-body
PET of a WT mouse and a WT rat (Figure 2B,E) revealed
that excretion of radioactivity to the bladder and intestines
was limited during the 1-h scan. Distribution patterns of
(R)-[11C]PAQ compared to the racemate are very similar,
except in the mouse kidney where an appreciable differ-
ence in uptake was observed (Figure 2C,F).
The biodistribution and metabolism of racemate
[11C]PAQ were previously reported in [10]. Here theFigure 3 Uptake in mammary glands and lung in MMTV-PyMT mice.
described as SUVmean and SUVmax values. SUV values for MMTV-PyMT mice
relation to body weight (BW) from data summed from 20 to 60 min after i
single dot; mean value and standard deviation of each group are indicated
a significant difference (unpaired t test, p < 0.005). (C) PET image of the MM
indicated with a circle in (A). (D) WT control mouse (13 weeks). The images a
blue and 0.1 < SUV < 0.6 = yellow. Image data are collected for 60 min, startin
glands, and the yellow arrow indicates an abnormal lung uptake. (E) TACs for
TACs are derived from volume-standardized ROIs drawn over the area with h
corresponding tissue of the mouse in (D).R-stereoisomer behaviour was examined in a few healthy
animals and compared with that of the racemate. In a
confirmatory metabolism assay, rat arterial blood was
sampled. At 30 and 60 min after injection, approximately
77% and 57%, respectively, of the radioactivity in the blood
was intact (R)-[11C]PAQ. The small amount of radioactiv-
ity found in the urine was polar metabolites according to
radio-HPLC. More detailed information can be found in
Additional file 1.
(R)-[11C]PAQ uptake in mammary glands and lung in
MMTV-PyMT mice
In all transgenic MMTV-PyMT mice (n = 9), the cancer-
ous mammary glands could be clearly visualized with
(R)-[11C]PAQ PET (Figure 3C). The mammary gland
uptake in MMTV-PyMT mice was significantly (unpaired(A) Lung and (B) mammary gland uptake after injection of (R)-[11C]PAQ
in black (n = 9) and WT in red (n = 3). All SUV values are calculated in
.v. administration of (R)-[11C]PAQ. Each individual is represented by a
by the horizontal and vertical blue lines, respectively. Asterisk indicates
TV-PyMT mouse (12 weeks) with highest SUVmax value in the lung;
re transparent isosurfaces with SUV > 1.5 = red colour, 0.7 < SUV < 1.4 =
g at injection of (R)-[11C]PAQ. Green arrows indicate cancerous mammary
lung and mammary gland tissue of the mice in (C) and (D), respectively.
ighest uptake in each respective tissue of the mouse in (C) and the
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controls (Figure 3B), both when comparing mean and
max SUV values. The lung uptake did not in general differ
significantly between the groups (Figure 3A) although the
two regions with the highest focal uptake were observed
in the lungs of MMTV-PyMT mice (Figure 3C).
[18 F]FDG uptake partially overlapped the uptake of (R)-
[11C]PAQ PET in mammary gland tissue in the MMTV-
PyMT animals but was more homogenously distributed in
the tumours (Figure 4). Uptake of [18 F]FDG could not be
detected in the lung tissue in any of the animals. Some
areas displaying obvious discrepancies in the uptake
of [18 F]FDG and (R)-[11C]PAQ were also observed
(Figure 4).
Ex vivo immunofluorescence and phosphor imaging
analyses
In order to corroborate that high levels of (R)-[11C]PAQ
uptake were related to elevated expressions of VEGFR2,
IF and PI analyses were performed on sections from
cancerous mammary gland tissue of the MMTV-PyMT.
Lung tissue, in which an increased uptake of (R)-[11C]
PAQ was observed with PET, was analysed for the pres-
ence of metastatic activity.
The radioactivity distribution (Figure 5C) in the section
correlated well with that of the VEGFR2 expressionFigure 4 MMTV-PyMT mouse scanned after injection with (R)-[11C]PA
(R)-[11C]PAQ and [18 F]FDG images are summed over 60 and 40 min, respec
the lungs with green lines. (A) Areas with the highest [18 F]FDG uptake are
fused with the MRI image. The green lines drawn over (A) and (B) indicate
mouse with fused [18 F]FDG, (R)-[11C]PAQ and MRI images. (D1-D3) Areas o
two tracers.(Figure 5B). When the most intensively stained areas
of VEGFR2 and CD31 overlaid the phosphor image,
correlation is even more precise (the radioactive hotspots
in Figure 5D1,D2). Radioactivity uptake was observed in
areas with high VEGFR2 but low CD31 expressions, but is
lower than in areas where both are co-localized. Relatively
low uptake of radioactivity was observed in areas with high
CD31 and low VEGFR2 expressions.
The metastases in the stained lung sections were charac-
terized by a higher tissue density compared to normal lung
tissue (Figure 6), intense VEGFR2 staining (Figure 6A1,B1)
and a marked PyMT-staining (Figure 6A2,B2). The PyMT-
specific antibody and the higher VEGFR2 staining
correlate well and show that neoangiogenesis is present
everywhere within the metastatic growth (Figure 6A3). A
distinct border can be seen between the metastatic tissue
and the normal lung tissue (Figure 6B3). This metastasis
could be observed in approximately 30 sequential sections
(25 μm). The section in Figure 6 is representative for the
observations.
Discussion
This study introduces the R-isomer of [11C]PAQ as a
noninvasive PET imaging biomarker for VEGFR2 ex-
pression. (R)-[11C]PAQ demonstrates favourable imaging
properties, including limited metabolism, rapid clearanceQ followed by [18 F]FDG 100 min later and MRI after euthanasia.
tively. Tumour areas are outlined with orange, and in (C2) and (D2)
shown as a white overlay over the MRI image. (B) (R)-[11C]PAQ images
the position of each transaxial image. (C1-C3) Transaxial images of the
f interest magnified, illustrating discrepancies in the uptake of the
Figure 5 Immunofluorescence and phosphor imaging of a representative mammary gland section from a 15-week-old MMTV-PyMT
mouse. Sectioning was performed 30 min after injection with (R)-[11C]PAQ. (A) Staining with DAPI (blue) and CD31 antibodies (yellow); the most
intensely CD31-stained areas are outlined. (B) Staining with DAPI and VEGFR2 antibodies (red); the most intensely VEGFR2-stained areas are
outlined. (C) Phosphor imaging displaying radioactivity distributions with an overlay (outlined) of areas with overlapping high VEGFR2 and CD31
expressions. (D1) Magnification of a region with high uptake of radioactivity (indicated with a green square in (A) to (C)) showing the corresponding
image with IF where the staining of CD31 and VEGFR2 are merged. (D2) Further magnification indicated by the blue square in (D1) showing VEGFR2
and CD31 co-localization in VEGFR2-positive blood vessels.
Samén et al. EJNMMI Research 2014, 4:17 Page 8 of 11
http://www.ejnmmires.com/content/4/1/17from the blood and rapid accumulation in the tumour tis-
sue. Using the MMTV-PyMT model of metastatic breast
cancer in mice, we have shown that (R)-[11C]PAQ canvisualize lesions with areas of ongoing neovascularization.
Ex vivo analysis corroborated that tracer uptake in cancer-
ous mammary gland tissue is highest in areas with high
Figure 6 IF staining of a lung section from the MMTV-PyMT mouse in Figure 4. DAPI (blue), VEGFR2 (red) and PyMT (green). (A1-A3)
Sections containing a metastasis with a diameter of approximately 1 mm. (B1-B3) Magnification of the corresponding area indicated with a
square in (A). (B3) Red and yellow arrows indicate metastasis and normal lung tissue, respectively. The border between the tissues is outlined
in white.
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regions displaying metastatic growth were also detected
using (R)-[11C]PAQ PET.
The R-isomer of [11C]PAQ was developed because of
its high selectivity for VEGFR2 and also to minimize po-
tential pharmacokinetic complications when using the
two enantiomers simultaneously. The importance of
stereoisomerism and possible problems associated with
racemic PET tracers has been discussed in [16], and it
was concluded that only pure stereoisomers should be
used for quantitative PET imaging. Although the review
focused on PET tracers for brain studies, several of the
pharmacokinetic parameters also apply for PET studies
in peripheral tissue. In our comparisons of the biodistri-
butions of (R)-[11C]PAQ and (R,S)-[11C]PAQ, only slight
differences were observed between species regarding
lung and liver uptake, while the uptake in the kidney
showed a larger difference in mouse (Figure 2C,F). The
R- and S-isomers may differ in nonspecific binding,
metabolic stability and distribution volumes, and these
differences can also be species dependent. Translation to
applications in human is therefore most likely improved
when only the more selective R-isomer is used.
VEGFR2 is abundantly expressed in the liver, lung and
kidney in the adult mouse. In secretory organs such as
the adrenal gland, the concentrations of VEGF are rela-
tively high and it is implied that the expressions of
VEGFR2 follow that of its ligand and are elevated as
well [17]. The presence of VEGFR2 might therefore
contribute to the high uptake of (R)-[11C]PAQ observed in
these organs (Figure 2A,D).As shown in Figure 5, the uptake of radioactivity and
the VEGFR2 expressions overlap in many areas, with the
best correlation in areas having both high VEGFR2 ex-
pressions and a higher microvascular density, indicated
by CD31 staining. This indicates that the tracer binds to
VEGFR2 in tumour tissue and that the degree of tracer
binding will also be related to the vascularization of the
tissue. On a microlevel, the importance of delivery of the
tracer to areas containing VEGFR2 is illustrated and
shows that (R)-[11C]PAQ is capable of visualizing tissue
with sufficient perfusion and ongoing angiogenesis. On a
macro PET imaging level, lesions and metastasis with
increased angiogenesis and neovascularization could be
readily visualized in a noninvasive fashion, as shown in
Figure 3.
Serial PET examinations with (R)-[11C]PAQ followed by
[18 F]FDG were performed to investigate whether this new
imaging biomarker could provide added information over
the clinically widely used [18 F]FDG. Both tracers accumu-
lated in the cancerous mammary gland tissue, though in
some instances with an obvious difference in uptake
patterns (Figure 4C3,D3). These differences may be due to
angiogenesis occurring in specific areas of the tumour
[18], while cells with high glucose utilization, indicated by
high [18 F]FDG uptake, are a general feature and they are
more evenly distributed within the tumour. In the
MMTV-PyMT model, multiple tumours at different stages
of tumour progression often develop simultaneously within
the mammary glands, which could further explain the
more heterogeneous uptake pattern of (R)-[11C]PAQ
observed in both Figures 4 and 5. The MMTV-PyMT
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http://www.ejnmmires.com/content/4/1/17mouse examined with PET and MRI (Figure 4) had a
marked uptake of (R)-[11C]PAQ but not [18 F]-FDG in the
lung. The IF results for lung sections from this animal
shown in Figure 6 confirm metastatic and highly angio-
genic activity in this area. These novel findings imply that
(R)-[11C]PAQ may be better than the most widely used im-
aging biomarker in oncology, [18 F]FDG, in visualizing
early metastatic growth in, for example, lung tissue.
Several small-molecule PET tracers targeting the tyrosine
kinase domain of the VEGFR2 have been synthesized and
are reviewed in [19,20]. Recently, ZD6474 has been labelled
with carbon-11, but in vivo results have not yet been
published [21]. In addition, a fluorine-18-labelled PAQ ana-
logue has been evaluated, with ex vivo binding to resected
tissue from human glioblastoma tumours shown [22].
Other approaches to visualize angiogenesis with PET are
protein-based VEGFR ligands [23,24] and arginylglycylas-
partic acid (RGD) peptides targeting integrin αVβ3 [25].
Promising imaging results have also been reported for
[89Zr]bevacizumab which binds to VEGF itself. An in-
creased uptake compared to labelled nonspecific control
proteins was observed in angiogenic tissue, and the uptake
levels were shown to correlate to angiogenic activity dur-
ing treatment and to the efficacy of anti-tumour drugs
[26,27]. PET tracers toward these and other targets may
potentially provide complementary information about an-
giogenic processes and can be useful for stratifying pa-
tients for therapies directed at these specific targets.
To be clinically useful, a PET tracer must not only
have good prognostic value but also be relatively easy to
obtain. The carbon-11 labelling procedure used in the
synthesis of (R)-[11C]PAQ is based on radiochemistry that
is readily performed in most PET facilities. The pharmaco-
kinetics examined in rodents indicates fast localization of
the tracer to its intended target (favourable for rapid 11C-
based imaging) and limited metabolism with high levels of
intact tracer during the initial tissue accumulation phase.
In addition, (R)-[11C]PAQ has a favourable biodistribution
for cancer studies in most parts of the body, except
possibly the liver and kidneys due to high normal uptakes
in these organs. Rapid distribution from the blood and a
tendency to plateau in tumours relatively quickly could
favour protocols for injecting and later moving to the PET
scanner for a shorter turnaround time. Since the carbon-
11 isotope has a short half-life of approximately 20 min,
same-day imaging of the patient with another PET tracer
could be performed to examine different biochemical and
biological characteristics of the lesions. All these factors
indicate that (R)-[11C]PAQ may be a promising PET im-
aging biomarker also in the clinical setting.
Conclusion
(R)-[11C]PAQ is a promising tracer that can be used to
visualize elevated levels of angiogenesis in primary solidtumours and likely also in tissues with metastatic
growth. The rapid accumulation of tracer in tumour
tissue provides good visualization within 60 min after
administration and is consistent with the short-lived
carbon-11 radionuclide. The biodistribution of the tracer
is favourable for detection and characterization of malig-
nant tissue particularly in the head and neck and thorax
regions in rodents. We suggest that the tracer should
be further evaluated preclinically and subsequently in
humans, with focus on establishing protocols to find
and assess local areas with angiogenic activity. Based
on our preclinical findings, we believe that a clinical
use of (R)-[11C]PAQ PET could be a very important
diagnostic complement for characterization of disease
and in selecting patients for anti-angiogenic therapy.
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